360 related articles for article (PubMed ID: 12124825)
21. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
[TBL] [Abstract][Full Text] [Related]
22. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.
Liu X; Zhang Y; Zhu Z; Ha M; Wang Y
Med Oncol; 2014 Aug; 31(8):85. PubMed ID: 24996799
[TBL] [Abstract][Full Text] [Related]
23. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease.
Kronborg G; Ostergaard C; Weis N; Nielsen H; Obel N; Pedersen SS; Price PA; Johansen JS
Scand J Infect Dis; 2002; 34(5):323-6. PubMed ID: 12069012
[TBL] [Abstract][Full Text] [Related]
24. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
[TBL] [Abstract][Full Text] [Related]
26. Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of preoperative carcinoembryonic antigen level in colorectal cancer in Tunisia.
Gara S; Meziou S; Mtar A; Ghanem A; Harzallah L; Rahal K; Boussen H; Guemira F
Tunis Med; 2012 Jan; 90(1):41-4. PubMed ID: 22311447
[TBL] [Abstract][Full Text] [Related]
28. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
[TBL] [Abstract][Full Text] [Related]
29. [The importance of determining the prognostic marker YKL-40 in serum and tissues].
Łata E; Gisterek I; Matkowski R; Szelachowska J; Kornafel J
Pol Merkur Lekarski; 2010 Jun; 28(168):505-8. PubMed ID: 20642115
[TBL] [Abstract][Full Text] [Related]
30. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
31. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level.
Park IJ; Choi GS; Lim KH; Kang BM; Jun SH
Ann Surg Oncol; 2009 Nov; 16(11):3087-93. PubMed ID: 19629600
[TBL] [Abstract][Full Text] [Related]
32. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
33. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
34. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.
Fan JT; Si XH; Liao Y; Shen P
Arch Gynecol Obstet; 2013 Jan; 287(1):111-5. PubMed ID: 22945838
[TBL] [Abstract][Full Text] [Related]
35. Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer.
Ytting H; Christensen IJ; Thiel S; Jensenius JC; Nielsen HJ
Hum Immunol; 2008 Jul; 69(7):414-20. PubMed ID: 18638656
[TBL] [Abstract][Full Text] [Related]
36. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
37. Plasma YKL-40: a potential new cancer biomarker?
Johansen JS; Schultz NA; Jensen BV
Future Oncol; 2009 Sep; 5(7):1065-82. PubMed ID: 19792974
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure.
Bessa X; Piñol V; Castellví-Bel S; Piazuelo E; Lacy AM; Elizalde JI; Piqué JM; Castells A
Ann Surg; 2003 Mar; 237(3):368-75. PubMed ID: 12616121
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
